Development of acute kidney injury during continuous infusion of vancomycin in septic patients

Infection
S CianferoniF S Taccone

Abstract

Few data are available on the occurrence of renal failure during continuous infusion of vancomycin in critically ill patients. We reviewed the data of all patients admitted to the intensive care unit (ICU) between January 2008 and December 2009 in whom vancomycin was given as a continuous infusion for more than 48 h in the absence of renal replacement therapy. We collected data on the doses of vancomycin and blood concentrations during therapy. Acute kidney injury (AKI) was defined as a daily urine output <0.5 ml/kg/h and/or an increase in the serum creatinine of ≥0.3 mg/dl from baseline levels during vancomycin therapy or within 72 h after its discontinuation. Multivariable logistic regression analysis was performed to identify predictors of AKI. Of 207 patients who met the inclusion criteria, 50 (24 %) developed AKI. These patients were more severely ill, had lower creatinine clearance at admission, were more frequently exposed to other nephrotoxic agents, had a longer duration of therapy, and had higher concentrations of vancomycin during the first 3 days of treatment (C(mean)). The C(mean) was independently associated with early AKI (within 48 h from the onset of therapy) and the duration of vancomycin administration with l...Continue Reading

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·B F Farber, R C Moellering
Sep 3, 2002·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Jaime Luis Lopes RochaLuzmila Terezinha Flenik Martins
Apr 12, 2003·Critical Care Medicine·Mitchell M LevyUNKNOWN SCCM/ESICM/ACCP/ATS/SIS
Feb 14, 2004·Intensive Care Medicine·Simon FinferJohn Myburgh
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E J Ellis-GrosseUNKNOWN Tigecycline 305 cSSSI Study Group
Jul 25, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Vinícius S ColaresRegina C R M Abdulkader
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Oct 25, 2006·Archives of Internal Medicine·Levita K HidayatAnnie Wong-Beringer
Mar 3, 2007·Critical Care : the Official Journal of the Critical Care Forum·Ravindra L MehtaUNKNOWN Acute Kidney Injury Network
May 29, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M E EichhornW H Hartl
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Thomas P LodiseG L Drusano
Oct 22, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Christine DieterichHanna H Ng
Jul 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano
Jan 28, 2010·The American Journal of Medicine·Kathleen A HazlewoodRonald G Hall
Nov 16, 2010·International Journal of Antimicrobial Agents·A JeurissenR Rutsaert
Dec 7, 2010·International Journal of Antimicrobial Agents·Annie Wong-BeringerPaul Beringer
Dec 25, 2010·The American Journal of Medicine·Lindsey PritchardK Bruce Bayley
Jan 13, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·O Rodriguez ColomoUNKNOWN Study Group of Infection in Critical Patients
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Jason A RobertsJeffrey Lipman
Jul 30, 2011·International Journal of Antimicrobial Agents·Håkan HanbergerUNKNOWN EPIC II Group of Investigators
Sep 29, 2011·Antimicrobial Agents and Chemotherapy·John A BossoPatrick D Mauldin
Oct 27, 2011·The Journal of Antimicrobial Chemotherapy·Maria Adriana CataldoNicola Petrosillo
Dec 14, 2011·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Jan 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard G WunderinkJean Chastre
Jan 31, 2012·Clinical Therapeutics·Ennie L CanoUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group
Feb 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J van HalD L Paterson
Feb 16, 2012·International Journal of Antimicrobial Agents·Eva Ocampos-MartinezFabio Silvio Taccone
May 15, 2012·Antimicrobial Agents and Chemotherapy·Christine B TengDavid N Schwartz
Oct 1, 2012·Clinical Pharmacology in Drug Development·Amélie MarsotNicolas Simon

❮ Previous
Next ❯

Citations

Jun 21, 2015·Expert Review of Anti-infective Therapy·Young R LeeRonald G Hall
Nov 25, 2014·Critical Care : the Official Journal of the Critical Care Forum·Katia DonadelloFabio Silvio Taccone
Sep 28, 2014·Journal of the American Medical Directors Association·T S Dharmarajan, Surya Davuluri
Mar 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J ChastreT Welte
Jan 6, 2016·Journal of Neurosurgical Anesthesiology·Omar TujjarFabio S Taccone
May 25, 2016·Antimicrobial Agents and Chemotherapy·Stefano CristalliniFabio Silvio Taccone
May 21, 2020·Therapeutic Drug Monitoring·Erik M van MaarseveenArthur R H van Zanten
Oct 14, 2019·Anaesthesia Critical Care & Pain Medicine·Marc LeoneBoris Jung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.